Showing results (231-240 of 973) with videos related to
Sort By:
Pageof 98
Currents in Pharmacy Teaching & Learning|May 23, 2026
Design and implementation of the extended 5-year doctor of pharmacy degree pathwayBrendan Stamper, Jeff Fortner, Madeline Fry, et al.Analytical Chemistry|September 26, 2007
Analysis of neuroactive amines in fermented beverages using a portable microchip capillary electrophoresis systemChristine N Jayarajah, Alison M Skelley, Angela D Fortner, et al.Journal of the American College of Surgeons|May 20, 2021
Teaching Effective Informed Consent Communication Skills in the Virtual Surgical ClerkshipJoyce H Pang, Esme Finlay, Sally Fortner, et al.Veterinary Anaesthesia and Analgesia|May 23, 2020
Determination of grapiprant plasma and urine concentrations in horsesSherry Cox, Carla Sommardahl, Chelsey Fortner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1986
Hypersensitivity reactions to teniposide (VM-26): an analysisP J O'Dwyer, S A King, C L Fortner, et al.Annals of Surgery|January 1, 1977
Tumor vascularity as a prognostic factor for hepatic tumorsD K Kim, R C Watson, L D Pahnke, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 3, 2007
Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequencesLee S Schwartzberg, Edward J Stepanski, Barry V Fortner, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 4, 2006
Patient and caregiver time burden associated with anaemia treatment in different patient populationsArthur C Houts, Geoffrey A Loh, Barry V Fortner, et al.Annals of Emergency Medicine|September 11, 2007
Thoracic compression fractures as a result of shock from a conducted energy weapon: a case reportJames E Winslow, William P Bozeman, Michael C Fortner, et al.Supportive Cancer Therapy|July 18, 2008
Symptom Burden for Patients with Metastatic Colorectal Cancer Treated with First-Line FOLFOX or FOLFIRI with and Without Bevacizumab in the Community SettingBarry V Fortner, Lee S Schwartzberg, Edward J Stepanski, et al.Pageof 98